Characterization of the humoral response to SARS-CoV-2, the etiological agent of COVID-19,
is essential to help control the infection. The neutralization activity of plasma from patients …

While the standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two
doses administered 3 weeks apart, some public health authorities are spacing these doses, …

SARS-CoV-2 is responsible for the coronavirus disease 2019 (COVID-19) pandemic, infecting
millions of people and causing hundreds of thousands of deaths. The Spike glycoproteins …

With the recent approval of highly effective coronavirus disease 2019 (COVID-19) vaccines,
functional and lasting immunity to severe acute respiratory syndrome coronavirus 2 (SARS-…

Neutralizing antibodies (NAbs) are effective in treating COVID-19, but the mechanism of
immune protection is not fully understood. Here, we applied live bioluminescence imaging (BLI) …

In the absence of effective vaccines and with limited therapeutic options, convalescent plasma
is being collected across the globe for potential transfusion to coronavirus disease 2019 (…

Emerging evidence indicates that both neutralizing and Fc-mediated effector functions of
antibodies contribute to protection against SARS-CoV-2. It is unclear whether Fc-effector …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) mediates viral
entry into cells and is critical for vaccine development against coronavirus disease 2019 (…

Emerging variants of concern for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
can transmit more efficiently and partially evade protective immune responses, …

The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses
administered three weeks apart. However, some public health authorities spaced these …